Quantcast

Latest Paliperidone Stories

2011-04-04 15:46:00

BEERSE, Belgium, April 4, 2011 /PRNewswire/ -- Janssen EMEA -- New data from an independent prospective study presented last week at the 19th European Congress of Psychiatry (EPA 2011) shows treatment with Risperdal® Consta® (risperidone long-acting injection (RLAI)) is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period.

2010-11-19 07:00:00

ORLANDO, Fla., Nov. 19, 2010 /PRNewswire/ -- Schizophrenia is a chronic and disabling brain disorder that affects 1 percent of the U.S. population and results in substantial medical and societal costs, in particular from use of health-care resources.

2010-09-14 09:00:00

HAMILTON, N.J., Sept. 14 /PRNewswire/ -- MedAvante, Inc., the leader in centralized expert evaluation of CNS disorders, announced today that the U.S.

2010-05-21 07:00:00

TITUSVILLE, N.J., May 21 /PRNewswire/ -- New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone long-acting therapy), also an injectable medicine to treat schizophrenia, will be presented next week at a major psychiatry meeting in New Orleans.

2010-04-12 07:00:00

WALTHAM, Mass., April 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Janssen's Invega Sustenna earns Decision Resources' proprietary clinical gold standard status for the treatment of schizophrenia in 2013.

2010-01-11 20:57:42

A study published today in the Archives of Internal Medicine examines the impact of a safety warning issued by the Food and Drug Administration for commonly prescribed antipsychotic medications.

2010-01-11 20:09:53

The use of atypical antipsychotics to treat elderly patients with dementia appears to have decreased following a 2005 Food and Drug Administration (FDA) advisory regarding the risks of these medications in this population.

2009-12-10 06:57:00

TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia.


Word of the Day
shotta
  • An armed gangster.
The word 'shotta' is an alteration of 'shooter'.